RecruitingPhase 1Phase 2NCT06329882

Doxycycline in Type II Diabetes

Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus


Sponsor

Mostafa Bahaa

Enrollment

60 participants

Start Date

Mar 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden


Eligibility

Min Age: 40 YearsMax Age: 60 Years

Inclusion Criteria1

  • Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5

Exclusion Criteria1

  • Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Interventions

DRUGSitagliptin 100mg

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes

DRUGDoxycyclin

Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.


Locations(1)

Tanta Unuversity

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06329882


Related Trials